Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...

Alnylam Pharmaceuticals (ALNY) shows strong price momentum, hitting new all-time highs on Aug. 11. ・ALNY has a 100% technical ...

Alnylam Pharmaceuticals Inc has a consensus price target of $397.96 based on the ratings of 28 analysts. The high is $570 issued by HC Wainwright & Co. on August 7, 2025.

Alnylam Pharmaceuticals , Inc. (NASDAQ:ALNY), a leader in RNA interference (RNAi) therapeutics, stands at a pivotal juncture as it seeks to capitalize on the burgeoning market for transthyretin ...

10 analysts have expressed a variety of opinions on Alnylam Pharmaceuticals (NASDAQ:ALNY) over the past quarter, offering a diverse set of opinions from bullish to bearish. In the table below, you ...

Alnylam Pharmaceuticals has seen its stock rise by 17% this year. The stock now trades at over 33x projected 2020 revenues, despite the fact that the company is likely to post another loss this year.

According to 20 analyst offering 12-month price targets in the last 3 months, Alnylam Pharmaceuticals has an average price target of $252.65 with a high of $405.00 and a low of $170.00.

Alnylam sues Moderna & Pfizer, claiming Covid-19 vaccines infringe lipid patent Alnylam Pharmaceuticals has proprietary lipid nanoparticle technology used in its FDA-approved RNA therapies.

The stock price of Alnylam Pharmaceuticals, a pharmaceutical company best known for its ribonucleic acid interference therapeutics for genetically defined diseases, has rallied around 50% over ...

In response to the company sharing a slew of positive developments with investors, shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) , a clinical-stage biotech focused on RNAi therapies, jumped 13% ...